Skip to main content
Third-party tested
Purity documentation available
Research supply chain
Compliance notice included
CJC-1295 (no DAC) / Ipamorelin 10 mg research peptide blend vial, Validated Peptides
99%+ Purity

Buy CJC-1295 (No DAC) / Ipamorelin Blend

This blend contains CJC-1295 (no DAC), the tetrasubstituted GHRH(1-29) analog also sold as Mod GRF 1-29, together with Ipamorelin, a pentapeptide ghrelin receptor agonist. The identity test on our lot confirms CJC-1295 WITHOUT DAC plus Ipamorelin at 5 mg each. The distinction from CJC-1295 with DAC matters: the DAC version carries a maleimide group that bonds the peptide to albumin and stretches its presence in plasma past 72 hours in rats, while the no-DAC form clears quickly and produces a short burst of GHRH receptor stimulation. The two components in this vial act on different receptors. GHRH analogs work on the GHRH receptor on pituitary somatotrophs, and Ipamorelin works on the GHRP receptor, where it released growth hormone from rat pituitary cells with potency and efficacy similar to GHRP-6 but, unusually for that class, without raising ACTH or cortisol even at amounts more than 200-fold above its effective concentration. Researchers combine the two pathways to study how convergent signals shape growth hormone output.

1
$69.99
We accept

CJC-1295 (no DAC) / Ipamorelin Certificate of Analysis

Third Party TestedLab Verifiable
Lab Verified3rd Party
99.9%
Purity
Passed full QC panel
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Full QC Panel
Purity (HPLC)99.9%
Net Peptide Content10.33mg
Identity (HPLC)Confirmed
Heavy Metals (ICP-MS)Pass
Microbial screen (PCR)No Growth
Endotoxin (USP <85>)NMT 0.05 EU/mL
Independent Lab Report
Lab Verified3rd Party
Pass
Fentanyl Screen
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Independent Lab Report
Lab Verified3rd Party
Pass
Identity
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Full QC Panel
Identity (HPLC)Confirmed
Independent Lab Report
Lab Verified3rd Party
10.33mg
Net Peptide Content
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Independent Lab Report
Lab Verified3rd Party
Pass
Heavy Metals
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Full QC Panel
Heavy Metals (ICP-MS)Pass
Independent Lab Report
Lab Verified3rd Party
Pass
Microbial Screen
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Full QC Panel
Microbial screen (PCR)No Growth
Independent Lab Report
Lab Verified3rd Party
Pass
Endotoxin
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Full QC Panel
Endotoxin (USP <85>)NMT 0.05 EU/mL
Independent Lab Report
Lab Verified3rd Party
99.9%
Purity
Passed full QC panel
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Full QC Panel
Purity (HPLC)99.9%
Net Peptide Content10.33mg
Identity (HPLC)Confirmed
Heavy Metals (ICP-MS)Pass
Microbial screen (PCR)No Growth
Endotoxin (USP <85>)NMT 0.05 EU/mL
Independent Lab Report
Lab Verified3rd Party
Pass
Fentanyl Screen
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Independent Lab Report
Lab Verified3rd Party
Pass
Identity
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Full QC Panel
Identity (HPLC)Confirmed
Independent Lab Report
Lab Verified3rd Party
10.33mg
Net Peptide Content
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Independent Lab Report
Lab Verified3rd Party
Pass
Heavy Metals
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Full QC Panel
Heavy Metals (ICP-MS)Pass
Independent Lab Report
Lab Verified3rd Party
Pass
Microbial Screen
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Full QC Panel
Microbial screen (PCR)No Growth
Independent Lab Report
Lab Verified3rd Party
Pass
Endotoxin
Lot #CJC -10MG-CD-27
TestedNov 12, 2026
Full QC Panel
Endotoxin (USP <85>)NMT 0.05 EU/mL
Independent Lab Report

CJC-1295 (no DAC) / Ipamorelin Specifications

Structured specifications and handling data

Molecular profile

Technical specifications

Type:Peptide Blend (GHRH Analog + Ghrelin Receptor Agonist)
CAS Number:170851-70-4 (Ipamorelin); N/A (CJC-1295 without DAC)
Molecular Weight:3367.9 g/mol (CJC-1295 no DAC) + 711.9 g/mol (Ipamorelin)
Amino Acids:34
Sequence:CJC-1295 without DAC (29aa) + Ipamorelin, Aib-His-D-2-Nal-D-Phe-Lys-NH2 (5aa)
Formula:C152H252N44O42 (CJC-1295 no DAC) + C38H49N9O5 (Ipamorelin)
PubChem Database
Storage requirements

Stability and handling

Lyophilized
Cold Storage
Light Sensitive
Storage TemperatureStore in a cool, dry place away from light; refrigerate at 2–8°C (36–46°F)
ReconstitutionSterile water or bacteriostatic water recommended
StabilityStable when stored properly; avoid repeated freeze-thaw cycles

Frequently researched together

Compounds commonly studied alongside this one.

CJC-1295 (no DAC) / Ipamorelin research overview

Growth hormone release from the pituitary is controlled by two separate inputs, and this blend contains one agonist for each. CJC-1295 without DAC is a modified GHRH(1-29) fragment that binds the GHRH receptor on somatotroph cells and runs the adenylyl cyclase and cyclic AMP cascade. Ipamorelin binds the GHRP receptor instead, the same receptor ghrelin uses. Pharmacological profiling with GHRP and GHRH antagonists confirmed that Ipamorelin works through the GHRP-like receptor rather than the GHRH one, which is what makes the pairing a two-pathway experiment rather than two versions of the same stimulus.

Ipamorelin is the selective member of its class, and that is the reason it appears in blends. In rat pituitary cells it matched GHRP-6 for potency and efficacy, and in conscious swine neither compound moved FSH, LH, prolactin or TSH. The difference showed up in the stress axis: GHRP-6 and GHRP-2 both raised ACTH and cortisol, while Ipamorelin did not, even at amounts more than 200-fold above its effective concentration for growth hormone release. A researcher studying the growth hormone axis gets fewer confounding hormonal changes to control for.

The no-DAC choice in the GHRH half is deliberate. The albumin-bonded version, CJC-1295 with DAC, stays in plasma past 72 hours in rats and, in healthy men, raised trough growth hormone 7.5-fold a week after a single injection while leaving pulse frequency and amplitude unchanged. Without the DAC, stimulation is short, so the pulse pattern itself becomes the variable rather than the floor beneath it. Ipamorelin has also been studied outside the endocrine question entirely, in rodent models of postoperative ileus, where repeated administration shortened the time to first bowel movement and increased fecal output, food intake and weight gain.

GHRH Receptor Signaling

The CJC-1295 component acts on pituitary GHRH receptors through the adenylyl cyclase and cyclic AMP cascade.

Ghrelin Receptor Agonism

Antagonist profiling placed the Ipamorelin component at the GHRP-like receptor, not the GHRH receptor.

Hormone Selectivity Studies

In swine, Ipamorelin left FSH, LH, prolactin, TSH, ACTH and cortisol unchanged while releasing growth hormone.

Secretion Pattern Research

Serial-sampling studies have compared short GHRH stimulation with the albumin-bonded DAC form for effects on pulse shape.

CJC-1295 (no DAC) / Ipamorelin Research Evidence

Published studies and concise summaries for research review.

Ipamorelin, the first selective growth hormone secretagogue
Raun K et al.

AI-generated summary of this research paper below.

The paper that introduced Ipamorelin and the reason it is the secretagogue of choice for blends. The pentapeptide was identified in a series lacking the central Ala-Trp dipeptide of GHRP-1. In primary rat pituitary cells it released growth hormone with potency and efficacy close to GHRP-6, and antagonist profiling showed it acts through a GHRP-like receptor rather than the GHRH receptor. In anesthetized rats and conscious swine its potency again tracked GHRP-6. The notable result is selectivity: none of the secretagogues tested changed FSH, LH, prolactin or TSH, but GHRP-6 and GHRP-2 raised ACTH and cortisol while Ipamorelin did not, even at more than 200-fold its effective amount for growth hormone release.
Research overview
Total Papers
60+
Year Range
1998+
Research status
Active
Peer-reviewed studies available
Research FAQ

CJC-1295 (no DAC) / Ipamorelin FAQs

Concise answers about laboratory context, handling, and documentation for this compound.

Laboratory compliance notice

All compounds sold by Validated Peptides are intended for in-vitro laboratory research only.

These materials are not approved by the FDA for human or animal use and are not intended for diagnostic, therapeutic, or clinical applications.

Purchasers are responsible for compliant handling, storage, and use within an appropriate laboratory environment.

Research Use Only
Not for Human Use
21+ Required